Education
About Us
Working with TipRanks
Follow Us
BiomX (PHGE)
:PHGE
Earnings Data
Report Date
Aug 14, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.26Last Year’s EPS
-0.7Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 15, 2025
|% Change Since: -5.45%
|Next Earnings Date:Aug 14, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress with positive clinical trial results and secured financing, although there was an increase in R&D expenses. Overall, the sentiment of the call is optimistic with a focus on future opportunities.Company Guidance
During the BiomX First Quarter 2025 Financial Results Conference Call, the company provided significant guidance on its clinical and financial milestones. BiomX reported a positive top-line result from its Phase 2 trial of BX211 in diabetic foot osteomyelitis, demonstrating safety and efficacy with a statistically significant reduction in ulcer size and depth. The company is planning to advance BX211 to a potential Phase 2-3 trial pending regulatory feedback and is exploring funding opportunities, with approximately $40 million in non-diluted funding from the U.S. Defense Health Agency. For BX004, a Phase 2b trial in cystic fibrosis is expected to report top-line results in Q1 2026, with a current cash runway into the first quarter of 2026 after a $12 million financing and warrant exercise. Additionally, the company highlighted a net loss reduction to $7.7 million in Q1 2025 from $17.3 million in Q1 2024, attributed to changes in warrant valuations. Research and development expenses rose to $5.3 million due to clinical trial preparations and increased costs following an acquisition.Positive Phase 2 Trial Results for BX211
BiomX announced positive top-line results from the Phase 2 trial evaluating BX211 for diabetic foot osteomyelitis, demonstrating safety and tolerability, with significant improvement in ulcer size and depth.
$12 Million Financing Secured
BiomX announced a $12 million financing, providing a financial runway into the first quarter of 2026, supporting ongoing clinical trials.
Reduced Net Loss
Net loss reduced to $7.7 million for Q1 2025, compared to $17.3 million in Q1 2024, primarily due to changes in warrant fair value.
PHGE Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
PHGE Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 15, 2025 | $0.55 | $0.56 | +1.82% |
Mar 25, 2025 | $0.63 | $0.58 | -7.94% |
Nov 14, 2024 | $0.72 | $0.75 | +4.17% |
Aug 15, 2024 | $1.84 | $1.63 | -11.41% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does BiomX (PHGE) report earnings?
BiomX (PHGE) is schdueled to report earning on Aug 14, 2025, TBA Not Confirmed.
What is BiomX (PHGE) earnings time?
BiomX (PHGE) earnings time is at Aug 14, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is PHGE EPS forecast?
PHGE EPS forecast for the fiscal quarter 2025 (Q2) is -0.26.